ArticleESMO open2022
Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma.
F Janku et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papercites it
ArticleESMO open2022
F Janku et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.